The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours

SP Blagden1, MA Foskett1, RA Fisher1, D Short1, S Fuller1, ES Newlands1 and MJ Seckl*,1

1Department of Medical Oncology, Charing Cross Hospital, London W6 8RF, UK

Little literature exists on the safety of early pregnancy following chemotherapy. Here we assess the rate of relapse and foetal outcome in women who have completed single and multi-agent chemotherapy for gestational trophoblastic tumours. The records of 1532 patients treated for persistent gestational trophoblastic tumours at Charing Cross Hospital between 1969 and 1998 were reviewed. Patients were defined as receiving single agent or multi-agent treatment. Relapse rates and foetal outcome were reviewed in the 230 patients who became pregnant within 12 months of completing chemotherapy. In the single agent group 153 (22%) of 691 patients conceived early. Three subsequently relapsed. In the multi-agent group, 77 (10%) of 779 patients conceived early, two then relapsed. Relapse rates were 2% (3 out of 153) and 2.5% (2 out of 77) for each group compared to 5% and 5.6% in the comparative non-pregnant groups. Outcomes of 230 early pregnancies: 164 (71%) delivered at full term, 35 (15%) terminations, 26 (11%) spontaneous abortions, three (1.3%) new hydatidiform moles and two (1%) stillbirths. Early pregnancies were more common in the single agent group (P<0.001), but spontaneous miscarriages and terminations were more likely to occur in the multi-agent group (P=0.04 and 0.03, respectively). Of the full-term pregnancies, three (1.8%) babies were born with congenital abnormalities. Patients in either group who conceive within 12 months of completing chemotherapy are not at increased risk of relapse. Though, we still advise avoiding pregnancy within 12 months of completing chemotherapy, those that do conceive can be reassured of a likely favourable outcome.

British Journal of Cancer (2002) 86, 26–30. DOI: 10.1038/sj/bjc/6600041 www.bjcancer.com

Keywords: trophoblastic disease; tumour; chemotherapy; pregnancy choriocarcinoma; relapse

Cancers in young women including gestational trophoblastic tumours (GTT) (Seckl and Newlands, 1997), lymphomas (Vose et al, 1988), leukaemias (Rai et al, 1981) and ovarian germ cell tumours (Williams, 1996) are frequently cured with chemotherapy. Fertility is usually preserved following chemotherapy in these women (Berkowitz et al, 1998; Woolas et al, 1998), but little is known about the risk of disease relapse or damage to the foetus in women who conceive soon after completing treatment (Rustin et al, 1984). Many physicians advise their patients to avoid pregnancy during the first year of follow-up. It is thought that this allows ova which have been damaged by chemotherapy to either repair or undergo degeneration, reducing the risk of foetal malformation and/or spontaneous abortion. The greatest risk of tumour relapse is within the first year of remission and early pregnancy can compromise both the surveillance systems used to detect relapse as well as the safe institution of subsequent therapies. In addition, it is possible that the hormonal changes associated with pregnancy could in some instances actually promote tumour growth and early recurrence.

Patients with GTT provide a very good example of these difficulties. Nearly all women with the disease are cured with either single agent or combination drug chemotherapy (Newlands et al, 1986). Fertility is usually preserved and the affected women frequently wish to become pregnant again as soon as possible. This is often because they were keen to start or continue their family when they developed their original tumour. However, they are routinely advised to avoid pregnancy for at least 1 year post chemotherapy because: (1) most relapses occur in the first year post-treatment and these relapses are detected by a rising hCG secreted by the tumour cells (a normal pregnancy also produces hCG and this acts as a smoke screen masking the detection of tumour relapse); (2) the potential risk of cytotoxic drug induced damage to the ova (Sieber and Adamson, 1975; Schilsky et al, 1980; Choo et al, 1985); (3) the potentially increased risk of pregnancy induced relapse.

The advice to avoid pregnancy for 1 year post-chemotherapy in women with GTT has been determined by theoretical risks rather than solid clinical evidence of risk to the mother and foetus. Consequently, women who do become pregnant during this period and their physicians are faced with a dilemma of whether to continue or terminate the pregnancy (Kohorn, 1999). Though there is increasing published evidence that early pregnancy after GTT chemotherapy as a whole does not compromise the foetus (Song et al, 1988; Tuncer et al, 1999a,b; Berkowitz et al, 2000) there is little data regarding the effect of early pregnancy on subsequent disease relapse in the patient. Few have assessed these risks separately for each treatment group, i.e. those receiving single or multi-agent treatment. Here we reviewed the number of relapses and the maternal and foetal outcomes in 230 women with GTT who became pregnant within 12 months of completing single or
multi-agent chemotherapy. These results were compared with the number of relapses in women who did not become pregnant during the first 12 months after treatment for GTT and with national statistics on foetal outcome in unaffected healthy women.

PATIENTS AND METHODS

We retrospectively reviewed the records of 1532 patients who were given chemotherapy at Charing Cross Hospital for GTT between December 1969 and January 1998 (Table 1). The patients were divided into two groups, one receiving 'single-agent' and the other 'multi-agent' chemotherapy. Patients in the 'single agent' group had low or medium risk disease according to the Charing Cross modification of the WHO GTT scoring system (World Health Organization Scientific Group, 1983) used to stage this disease and received methotrexate and folic acid (MTX/FA). The 'multi-agent' group was composed of those with medium or high-risk disease requiring treatment with either MTX/FA plus actinomycin D or combination drug chemotherapy most frequently consisting of etoposide, methotrexate and actinomycin D (EMA) alternating weekly with cyclophosphamide and vincristine (CO) (Bower and Newlands, 1997). Chemotherapy was completed once hCG levels had fallen to within the normal range and remained there for at least 6 weeks. Patients initially given 'single-agent' treatment but whose hCG levels remained elevated (usually because of methotrexate-resistance) then received multi-agent chemotherapy and were included in the 'multi-agent' group (Omura, 2000) in this study. Patients who died within weeks of diagnosis or while still receiving treatment were excluded from the study.

The outcome of patients who had become pregnant within 12 months of completing chemotherapy was then reviewed. Their relapse rate was compared to the relapse rate of patients that had not become pregnant within 12 months. Pregnancy and foetal outcomes in both groups were also compared.

Statistical considerations

Statistical analysis of the results was performed using the Fisher’s exact test. The values were considered significant at $P \leq 0.05$.

Table 1  Patient characteristics

| Total | Single-agent chemotherapy | Multi-agent chemotherapy |
|-------|---------------------------|-------------------------|
| Total number of patients | 1532 | 682 | 850 |
| Early patient deaths | 72 | 1 | 71 |
| Total minus deaths | 1460 | 681 | 779 |
| Patient age range (median) | 13.8–58 | 13.8–56.6 | 15.5–58 |

Table 2  Pregnancy and relapse characteristics

| Total (%) | Single-agent (%) | Multi-agent (%) | $P$ value |
|-----------|------------------|-----------------|-----------|
| Total number of patients | 1460 | 681 (47) | 779 (53) | 0.02* |
| Total number of relapses | 78 (5.3) | 34 (5) | 44 (5.6) | 0.64 |
| Relapses within 12 months (as percentage of total relapses) | 58 (74) | 22 (65) | 36 (82) | 0.12 |
| Early pregnancies (conceived within 12 months) | 380 (16) | 153 (22) | 77 (10) | <0.001* |
| Early pregnancies reaching term (as percentage of total early pregnancies) | 5 (2) | 3 (2) | 2 (2.6) | 1 |
| Spontaneous miscarriages | 164 (71) | 120 (78) | 44 (57) | 0.1 |
| Early pregnancies terminated | 26 (11) | 12 (8) | 14 (18) | 0.04* |
| Still births | 35 (15) | 17 (11) | 18 (23) | 0.03* |
| New hydatidiform moles | 2 (0.9) | 2 (0.9) | 0 | N/A |
| Congenital abnormalities in babies delivered | 3 (1.3%) | 2 (1.3%) | 1 (1.2%) | 0.7 |

*P-value $\leq 0.05$ indicates statistical significance.
Pregnancy and relapse after trophoblastic disease

SP Blagden et al

microsatellite genotyping as previously described (Seckl et al, 2000) in order to determine the causative pregnancy. The results shown in Table 4 demonstrate that the choriocarcinoma arose from the preceding complete mole. All five patients were subsequently cured with combination chemotherapy with an additional hysterectomy in one case (median follow-up 9 years range 5 – 30). Moreover, all their infants thrived (Table 3).

DISCUSSION

This study aimed to investigate the safety of early conception following chemotherapy for GTT in the single and multi-agent treatment groups. This was achieved by comparing the pregnancy outcomes, rates of disease relapse and development of second tumours to those of other women on our GTT database or in the general population.

Relapse

Of the 230 patients who conceived in the first 12 months of follow-up only five relapsed. All of these had had a previous complete hydatidiform mole. In one patient we confirmed that the subsequent choriocarcinoma at relapse originated from the previously treated molar pregnancy and was not a new post-term choriocarcinoma. Indeed, in our experience, the preceding hydatidiform mole is usually the cause of subsequent GTT even in the case of several intervening pregnancies (unpublished observations). We therefore believe that the other four cases developed their relapsing GTT from the previous molar pregnancy.

Our results confirmed that relapse is most likely to occur within 12 months of completing chemotherapy. Patients who have received more intensive chemotherapy do not seem to be at a higher risk of disease recurrence than those on single agent treatment. In addition, the incidence of relapse is not increased in patients who become pregnant within 12 months of completing treatment.

Time to conception and termination rate

There were fewer early pregnancies in the women who had received multi-agent chemotherapy. Of those pregnancies, the majority occurred beyond 6 months from their treatment completion. This is likely to be due to anovulation following more intensive treatment. Studies have shown that the ovary has fewer primordial follicles following chemotherapy (Sieber and Adamson, 1975).

Higher risk patients are also less likely to feel physically well after multi-agent chemotherapy and prefer to follow GTT guidelines and delay conceiving. This is another factor contributing to the fewer pregnancies in this group and is also reflected in their significantly greater number of terminations.

By contrast, the low-risk, methotrexate-containing chemotherapy group had a less marked difference in distribution of pregnancies over the 12 months following their chemotherapy. This is because single agent methotrexate causes fewer menstrual irregularities with most patients maintaining a normal menstrual cycle throughout their treatment. Generally, these patients have a greater sense of physical well-being after treatment which contributes to the higher number of conceptions and fewer terminations. Also physicians may be more inclined to institute close monitoring during their pregnancy rather than to advise elective abortion.

Miscarriages

Patients in the multi-agent group had a significantly higher number of spontaneous miscarriages than those receiving single agent treatment. This again indicates that higher intensity treatment is more likely to have adverse physiological effects. Because hCG monitoring of patients in this study continued after their chemotherapy, a pregnancy would be diagnosed earlier. We would therefore expect higher rates of reported miscarriage than occur in the general population whose hCG levels are not routinely monitored. Thus we compared our results with those of a study of 217 pregnancies in women whose hCG levels were prospectively measured with a similar definition of ‘serological pregnancy’ (Ellish et al, 1996). This study recorded a miscarriage rate of 13.7% which compares very favourably with our overall miscarriage rate of 11%. Other studies have reported early miscarriage rates affecting between 8% (Whittaker et al, 1983) and 61% (Edmonds et al, 1982) of pregnancies. Consequently, though patients in the multi-agent group appeared to be at greater risk of miscarriage (18%) than those in the single agent group (8%), it is unlikely that they are at greater risk than that of the general population.

Foetal malformation and still birth

Congenital malformations (as defined by the Office for National Statistics (1999)) occurred in 1.3% of the 230 pregnancies...
conceived within 12 months of chemotherapy. This did not appear to differ from the 1.6% rate recorded in the general population of England and Wales between 1971 and 1998 (Office for National Statistics, 1999). Moreover, our results are in accordance with previous studies showing no correlation between foetal malformation and previous chemotherapy for GTT (Song et al, 1988; Tuncer et al, 1999a,b; Berkowitz et al, 2000). Between 1970 and 1997, the Office for National Statistics recorded an average of 7.08 stillbirths per 1000 pregnancies reported per year in the general population of England and Wales (0.7%) (Office for National Statistics, 1998–1999). Thus, the 1% still birth rate recorded in this study compared favourably with these figures.

Second hydatidiform mole

In this study, three patients (1.3%) developed new hydatidiform moles, different in histology to their previous invasive GTT and therefore not defined as relapsed or recurrent disease. The risk of second molar disease complicating a subsequent pregnancy has been estimated at around 1% (Vose et al, 1988) and in a recent retrospective study of 5030 trophoblastic disease patients there was a recurrent molar pregnancy rate of 0.7% (Lorigan et al, 2000). Thus early pregnancy does not appear to increase the chance of having a second molar pregnancy.

Conclusion

Early pregnancy following chemotherapy for GTT does not increase disease relapse. In terms of foetal outcomes, pregnancy following single agent (low risk) treatment has no effect on rates of miscarriage, still birth or congenital malformation. While early pregnancy after multi-agent treatment does not appear to increase the rate of still birth or congenital malformation, it may transiently reduce fertility and relatively increase the chance of miscarriage. Physicians should still advise patients to avoid pregnancy for 1 year after chemotherapy treatment for GTT. This is because, patients are at greatest risk of relapse during this time and the rising hCG of pregnancy can prevent early detection and diagnosis of disease recurrence. This could place both the patient and foetus at risk. However, patients who do become pregnant and are desperate to have a child can be assured of a probable favourable outcome.

ACKNOWLEDGEMENTS

We would like to thank the Department of Health and The Cancer Research Campaign for their kind support.

REFERENCES

Berkowitz RS, Im SS, Bernstein MR, Goldstein DP (1998) Gestational trophoblastic disease: subsequent pregnancy outcome including repeat molar pregnancy. J Reprod Med 43: 81 – 86
Berkowitz RS, Tuncer ZS, Bernstein MR, Goldstein DP (2000) Management of gestational trophoblastic diseases: subsequent pregnancy experience. Semin Oncol 27: 678–685

Additional content:

Table 3  Foetal and maternal outcome in the five patients who relapsed after early pregnancy

| Case | Age | Initial diagnosis and treatment | Weeks from treatment end until conception | Weeks from delivery until relapse | Foetal outcome | Maternal outcome |
|------|-----|--------------------------------|------------------------------------------|----------------------------------|----------------|-----------------|
| 1    | 27  | CHM Single-agent               | 48                                       | Relapsed with pulmonary metastases during 36th week of pregnancy | Emergency caesarean section at 37 weeks. Healthy baby | Diagnostic thoracotomy, multiagent chemotherapy. Remission 6 years |
| 2    | 19  | CHM Mult-Agent                 | 49                                       | 37 weeks                         | Standard vaginal delivery at term. Healthy baby | Multiagent chemotherapy +hysterectomy. Remission 30 years |
| 3    | 28  | CHM Single-agent               | 2                                        | 6 weeks                          | Standard vaginal delivery at term. Healthy baby | Multiagent chemotherapy +hysterectomy. Remission 26 years |
| 4    | 21  | CHM Mult-Agent                 | 25                                       | 19 weeks                         | Standard vaginal delivery at 39 weeks. Healthy baby | Hysterectomy+multiagent chemotherapy+thoracotomy. Remission 5 years |
| 5    | 23  | CHM Mult-Agent                 | 39                                       | 9 weeks                          | Standard vaginal delivery at 42 weeks. Healthy baby | Multiagent chemotherapy. Remission 9 years |

*CHM: Complete hydatidiform mole.

Table 4  Microsatellite genotyping of Case 1 from Table 3

| Microsatellite marker | Mfd50 | D10S179 | VWF | D15S659 |
|----------------------|-------|---------|-----|---------|
| Patient              | 175–189 | 125–135 | 138–146 | 178–190 |
| Child                | 175–179 | 119–135 | 138–142 | 178–194 |
| Tumour               | 185    | 119     | 142   | 194     |
| Partner              | 179–185 | 113–119 | 142–150 | 194     |
| HM                   | 185    | 119     | 142   | 194     |

Allele sizes (in base pairs) for microsatellite markers identified in DNA from the patient, her partner, the child of the pregnancy antecedent to the tumour, the tumour and her previous molar pregnancy. The genotype of the child and the tumour are different. The child has both a maternal and a paternal (bold figures) contribution to the genome. However, the tumour has only a paternal contribution to the genome suggesting an androgenetic origin. Comparison of the genotype and the tumour and her previous molar pregnancy. The genotype of the child and the tumour and the earlier molar pregnancy confirm this to have been the causative pregnancy.

© 2002 The Cancer Research Campaign
